文献速递儿童呼吸儿童感染儿童消化与营养

产前与婴儿期暴露于抑酸药物与儿童过敏性疾病风险

Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children.
PubMed 文献 · JAMA Pediatr · 2023-01-01

这项基于韩国全国母婴 linkage 数据库的队列研究,纳入4 149 257对母婴,采用倾向评分匹配和同胞匹配分析。结果显示产前暴露于抑酸药物与子代过敏性疾病无关联,但婴儿期暴露与哮喘风险升高相关,且同胞匹配后哮喘风险仍显著。

要点

  • 产前暴露于抑酸药物与子代过敏性疾病无显著关联。
  • 婴儿期暴露于抑酸药物与哮喘风险升高相关,同胞匹配后仍显著。
  • 临床为婴儿处方抑酸药物时需权衡获益并密切监测安全性信号。

核心结论

  • 产前暴露于抑酸药物与子代过敏性疾病无关联。
  • 婴儿期暴露于抑酸药物与哮喘风险升高相关,但幅度较既往报告更温和。

研究设计与样本

  • 采用倾向评分匹配和同胞匹配分析,Cox比例风险回归估计HR及95%CI。

主要发现

  • 产前暴露倾向评分匹配分析纳入808 067对,整体过敏性疾病HR 1.01(95%CI 1.01-1.02),同胞匹配分析HR 1.01(95%CI 0.997-1.01)不显著。
  • 婴儿期暴露倾向评分匹配分析纳入84 263对,整体过敏性疾病HR 1.06(95%CI 1.05-1.07),哮喘HR 1.16(95%CI 1.14-1.18),食物过敏HR 1.28(95%CI 1.10-1.49)。
  • 同胞匹配分析中婴儿期暴露与哮喘风险仍显著升高(HR 1.13,95%CI 1.09-1.17)。
  • H2RA和PPI分别分析结果相似,所有敏感性分析稳健。

关键数值与推荐

  • 产前暴露倾向评分匹配整体过敏性疾病HR 1.01(95%CI 1.01-1.02),同胞匹配HR 1.01(95%CI 0.997-1.01)。
  • 婴儿期暴露倾向评分匹配整体过敏性疾病HR 1.06(95%CI 1.05-1.07),哮喘HR 1.16(95%CI 1.14-1.18)。
  • 婴儿期暴露同胞匹配哮喘HR 1.13(95%CI 1.09-1.17)。

临床怎么用

  • 产前使用抑酸药物无需因过敏风险担忧子代过敏性疾病。
  • 婴儿期处方抑酸药物应仔细权衡获益,并密切监测哮喘等安全性信号。

局限性

  • 观察性研究设计,尽管采用倾向评分和同胞匹配,仍可能存在残余混杂。
  • 产前暴露同胞匹配分析中关联不显著,提示家族内混杂可能影响结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Existing observational data have indicated positive associations of acid-suppressive medication (ASM) use in prenatal and early life with allergic diseases in children; however, no study to date has accounted for confounding by indication or within-familial factors. OBJECTIVE: To evaluate the association of prenatal or infant exposure to ASMs with risk of allergic diseases in children. DESIGN, SETTING, AND PARTICIPANTS: This nationwide, cohort study included data from South Korea's National Health Insurance Service mother-child-linked database from January 1, 2007, to December 31, 2020. Participants included mother-child pairs of neonates born from April 1, 2008, to December 31, 2019. EXPOSURES: Prenatal and infant exposure to ASMs (histamine 2 receptor antagonists [H2RAs] and proton pump inhibitors [PPIs]). MAIN OUTCOMES AND MEASURES: Composite and individual outcomes of allergic diseases (asthma, allergic rhinitis, atopic dermatitis, and food allergy) in children (followed up to 13 years of age) were assessed. The ASM-exposed individuals were compared with unexposed individuals in propensity score (PS)-matched and sibling-matched analyses to control for various potential confounders and within-familial factors. Hazard ratios (HRs) with 95% CIs were estimated using Cox proportional hazards regression models. RESULTS: The study included 4 149 257 mother-child pairs. Prenatal exposure analyses included 808 067 PS-matched pairs (763 755 received H2RAs, 36 529 received PPIs) among women with a mean (SD) age of 31.8 (4.2) years. The PS-matched HR was 1.01 (95% CI, 1.01-1.02) for allergic diseases overall (asthma: HR, 1.02 [95% CI, 1.01-1.03]; allergic rhinitis: HR, 1.02 [95% CI, 1.01-1.02]; atopic dermatitis: HR, 1.02 [95% CI, 1.01-1.02]; food allergy: HR, 1.03 [95% CI, 0.98-1.07]); in sibling-matched analyses, the HRs were similar to those of PS-matched analyses but were not significant (allergic diseases: HR, 1.01; 95% CI, 0.997-1.01). Infant exposure analyses included 84 263 PS-matched pairs (74 188 received H2RAs, 7496 received PPIs). The PS-matched HR was 1.06 (95% CI, 1.05-1.07) for allergic diseases overall (asthma: HR, 1.16 [95% CI, 1.14-1.18]; allergic rhinitis: HR, 1.02 [95% CI, 1.01-1.03]; atopic dermatitis: HR, 1.05 [95% CI, 1.02-1.08]; food allergy: HR, 1.28 [95% CI, 1.10-1.49]); asthma risk (HR, 1.13; 95% CI, 1.09-1.17) remained significantly higher among children exposed to ASMs during infancy in sibling-matched analyses. The findings were similar for H2RAs and PPIs analyzed separately and were robust across all sensitivity analyses. CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest that there is no association between prenatal exposure to ASMs and allergic diseases in offspring. However, infant exposure to ASMs was associated with a higher risk of developing asthma, although the magnitude was more modest than previously reported. Clinicians should carefully weigh the benefits of prescribing ASMs to children, accompanied by subsequent close monitoring for any clinically relevant safety signals.

来源:JAMA Pediatr,查看原文。版权归原作者所有。

引用

  1. Noh Y, Jeong HE, Choi A, et al. Prenatal and Infant Exposure to Acid-Suppressive Medications and Risk of Allergic Diseases in Children. JAMA Pediatr. 2023. PMID: 36622684. doi:10.1001/jamapediatrics.2022.5193

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。